CAR T Cell therapy miedzo, Glioblastoma, glioblastoma miedzo, gliomas
Kuchengeteka uye Kubudirira Kudzidza kweAnti-B7-H3 CAR-T Cell Therapy yeRecurrent Glioblastoma
Kurume 2023: Rudzi rweChidzidzo : Yekupindira (Kuyedzwa Kwekiriniki) Hunofungidzirwa Kunyoresa : 30 vatori vechikamuKugoverwa: N/AIKupindira Muenzanisi: Inotevedzana AssignmentIntervention Model Tsananguro: "3+3" dhizaini inoshandiswa kuona Maximum.
CAR T Cell therapy miedzo, miedzo yakawanda myeloma
Muedzo wekiriniki paCAR-T Cell kurapwa kune varwere vane BCMA/TACI-positive vakadzoka zvakare uye/kana refractory multiple myeloma.
Pfupiso pfupi: Chidzidzo cheAPRIL CAR-T masero ekurapa kune varwere vane BCMA/TACI yakanaka yakadzokororwa uye/kana refractory akawanda myeloma Tsanangudzo Yakadzama: Urwu ndirwo ruoko rumwe, rakavhurika-label, si.
bhora, Bhora Miedzo, CAR T Cell therapy miedzo, Clinical trials, Leukemia, Leukemia miedzo, Miedzo muChina
Kliniki yekuyedza kunyorera Bhora CAR T-Cell kurapwa
16 Kurume 2023: Kurapwa kwegomarara kuri kuvandudzwa nemishonga mitsva yeimmunotherapeutic inonangana neiyo microenvironment panzvimbo yebundu. T masero ane chimeric antigen receptors (CAR) ari kuongororwa zvakanyanya.